The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Open accessAbstract
AIMS/HYPOTHESIS: The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 (n-3) carboxylic acids (OM-3CA), individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). METHODS: This randomised placebo-controlled double-blind parallel-group study was performed at five clinical research centres at university hospitals in Sweden. 84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. Each group received oral doses of one of the following: 10 mg dapagliflozin (n = 21), 4 g OM-3CA (n = 20), a combination of both (n = 22) or placebo (n = 21). The primary endpoint was liver fat content assessed by MRI (proton density fat fraction [PDFF]) and, in addition, total liver volume and markers of glucose and lipid metabolism as well as of hepatocyte injury and oxidative stress were assessed at baseline and after 12 weeks of treatment (completion of the trial). RESULTS: (3.5) and liver PDFF 18% (9.3). All active treatments significantly reduced liver PDFF from baseline, relative changes: OM-3CA, -15%; dapagliflozin, -13%; OM-3CA + dapagliflozin, -21%. Only the combination treatment reduced liver PDFF (p = 0.046) and total liver fat volume (relative change, -24%, p = 0.037) in comparison with placebo. There was an interaction between the PNPLA3 I148M polymorphism and change in liver PDFF in the active treatment groups (p = 0.03). Dapagliflozin monotherapy, but not the combination with OM-3CA, reduced the levels of hepatocyte injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase (γ-GT), cytokeratin (CK) 18-M30 and CK 18-M65 and plasma fibroblast growth factor 21 (FGF21). Changes in γ-GT correlated with changes in liver PDFF (ρ = 0.53, p = 0.02). Dapagliflozin alone and in combination with OM-3CA improved glucose control and reduced body weight and abdominal fat volumes. Fatty acid oxidative stress biomarkers were not affected by treatments. There were no new or unexpected adverse events compared with previous studies with these treatments. CONCLUSIONS/INTERPRETATION: Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat content. Dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and FGF21, suggesting a disease-modifying effect in NAFLD. TRIAL REGISTRATION: ClinicalTrials.gov NCT02279407 FUNDING: The study was funded by AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these weight loss effects are limited by a compensatory increase in food intake [150,151].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,228
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Flagged first, then by citations
Cited by
Sorted by citations
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 829
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
ESPEN practical guideline: clinical nutrition in liver disease
Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
Bonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 322
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Li, R., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 347
Evolution of NAFLD and Its Management
Mundi, M. S., Velapati, S. R., Patel, J. R., Kellogg, T. A., Dayyeh, B. K. A., & Hurt, R. T. (2019) · Nutrition in Clinical Practice · doi:10.1002/ncp.10449 · Cited by 299
Latva-Rasku, A., Honka, M.-J., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., Kirjavainen, A. K., Saunavaara, V., Iozzo, P., Johansson, L., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1569 · Cited by 253
Self-citationNonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193
Marchisello, S., Pino, A. D., Scicali, R., Urbano, F., Piro, S., Purrello, F., & Rabuazzo, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081948 · Cited by 202
Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
Tana, C., Ballestri, S., Ricci, F., Vincenzo, A. D., Ticinesi, A., Gallina, S., Giamberardino, M. A., Cipollone, F., Sutton, R., Vettor, R., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16173104 · Cited by 189
Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 196
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 205
Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s233538 · Cited by 199
Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15738 · Cited by 169
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R. S., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 187
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Ανδρουτσάκος, Θ., Ansari, N. N., Bakasis, A., Kyrou, I., EFSTATHOPOULOS, E. P., Randeva, H. S., & Kassi, E. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 176
Gaborit, B., Ancel, P., Abdullah, A., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M. J., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01237-2 · Cited by 174
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 167
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.008 · Cited by 154
Arab, J. P., Dirchwolf, M., Álvares‐da‐Silva, M. R., Francisco Barrera, M., Benítez, C., Castellanos, M., Castro‐Narro, G., Chávez-Tapia, N. C., Chiodi, D., Cotrim, H. P., et al. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.09.006 · Cited by 146
Lee, C.-H., Fu, Y., Yang, S., & Chi, C. (2020) · Nutrients · doi:10.3390/nu12092769 · Cited by 148
Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 141
Xia, M., Bian, H., & Gao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00877 · Cited by 139
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 142
Seferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1954 · Cited by 136
Takeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 131
Shen, Y., Cheng, L., Xu, M., Wang, W., Wan, Z., Xiong, H., Guo, W., Cai, M., & Xu, F. L. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155657 · Cited by 118
Oscarsson, J., Önnerhag, K., Risérus, U., Sundén, M., Johansson, L., Jansson, P., Moris, L., Nilsson, P. M., Eriksson, J. W., & Lind, L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.08.003 · Cited by 114
Self-citationAdvances in multi-omics study of biomarkers of glycolipid metabolism disorder
Fang, X., Miao, R., Wei, J., Wu, H., & Tian, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.10.030 · Cited by 120
Wei, Q., Xu, X., Guo, L., Li, J., & Li, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.635556 · Cited by 109
Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 109
Phrueksotsai, S., Pinyopornpanish, K., Euathrongchit, J., Leerapun, A., Phrommintikul, A., Buranapin, S., Chattipakorn, N., & Thongsawat, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15580 · Cited by 104
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 108
Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 100
Raj, H., Durgia, H., Palui, R., Kamalanathan, S., Selvarajan, S., Kar, S. S., & Sahoo, J. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i2.114 · Cited by 97
Gastaldelli, A., Repetto, E., Guja, C., Hardy, E., Han, J., Jabbour, S. A., & Ferrannini, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13907 · Cited by 81
Lopez, A., & Pajimna, J. A. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-52603-5 · Cited by 91
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 79
Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01861-9 · Cited by 75
Xing, B., Zhao, Y., Dong, B., Zhou, Y., Lv, W., & Zhao, W. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13237 · Cited by 77
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 76
The hepatic lipidome: From basic science to clinical translation
ten Hove, M., Pater, L. V., Storm, G., Weiskirchen, S., Weiskirchen, R., Lammers, T., & Bansal, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.027 · Cited by 73
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74
Lin, X.-F., Cui, X.-N., Yang, J., Jiang, Y.-F., Wei, T.-J., Xia, L., Liao, X.-Y., Li, F., Wang, D.-D., Li, J., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01389-3 · Cited by 69
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. J. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 71
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kim, K., & Lee, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0137 · Cited by 69
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Ala, M. (2021) · Endocrinology · doi:10.1210/endocr/bqab157 · Cited by 71
Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
Branković, M., Jovanović, I., Dukić, M., Radonjić, T., Oprić, S., Klašnja, S., & Zdravkovic, M. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095146 · Cited by 72
Bray, J. J. H., Foster-Davies, H., & Stephens, J. W. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108368 · Cited by 64
Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children
Spooner, M. H., & Jump, D. Β. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000539 · Cited by 64
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use
Spooner, M. H., & Jump, D. Β. (2023) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061021-030223 · Cited by 63
Beygi, M., Ahi, S., Zolghadri, S., & Stanek, A. (2024) · Nutrients · doi:10.3390/nu16142220 · Cited by 69
Mulder, S., Hammarstedt, A., Nagaraj, S. B., Nair, V., Ju, W., Hedberg, J., Greasley, P. J., Eriksson, J. W., Oscarsson, J., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14018 · Cited by 58
Self-citationShi, M., Zhang, H., Wang, W., Zhang, X., Liu, J., Wang, Q., Wang, Y., Zhang, C., Guo, X., Qiao, Q., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108610 · Cited by 65
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 62
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 69
Lee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 57
Combination Therapies for Nonalcoholic Fatty Liver Disease
Makri, E. S., Makri, E., & Pοlyzos, S. A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071166 · Cited by 54
Arrese, M. A., Francisco Barrera, M., Triantafilo, N., & Arab, J. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1649981 · Cited by 56
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kim, K., Lee, B., Kim, Y. J., Lee, D. H., Soo, B., & Park, C. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0034 · Cited by 55
Cheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W., Yuen, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000855 · Cited by 56
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 59
NRF-2 and nonalcoholic fatty liver disease
Solano-Urrusquieta, A., Morales‐González, J. A., Castro‐Narro, G., Reyes, E. C., Flores-Rangel, P. D., & Fierros-Oceguera, R. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2019.11.010 · Cited by 54
Harreiter, J., Just, I., Leutner, M., Bastian, M., Brath, H., Schelkshorn, C., Klepochová, R., Krššák, M., & Kautzky‐Willer, A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14319 · Cited by 57
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Ballestri, S., Mantovani, A., Byrne, C. D., Lonardo, A., & Targher, G. (2021) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.05 · Cited by 52
Dwinata, M., Putera, D., Hasan, I., & Raharjo, M. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.102173 · Cited by 51
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 57
Yip, A. S. Y., Leong, S., Teo, Y. H., Teo, Y. N., Syn, N. L. X., See, R. M., Wee, C. F., Chong, E. Y., Lee, C., Chan, M. Y., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221083509 · Cited by 55
Avogaro, A., Fadini, G. P., & Prato, S. D. (2019) · Diabetes Care · doi:10.2337/dc19-1410 · Cited by 50
Cusi, K. J. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 53
Ng, C. H., Lin, S. Y., Chin, Y. H., Lee, M. H., Syn, N. L. X., Goh, X. L., Koh, J. H., Quek, J., Tan, D. J. H., Mok, S. F., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.09.013 · Cited by 52
Wang, X., Wu, N., Sun, C., Jin, D., & Lu, H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01085-y · Cited by 54
Liver and insulin resistance: New wine in old bottle!!!
Patel, B. M., & Goyal, R. K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172657 · Cited by 51
ESTERLINE, R. L., Oscarsson, J., & Burns, J. M. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 51
Self-citationSGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives
Morciano, C., Gugliandolo, S., Capece, U., Giuseppe, G. D., Mezza, T., Ciccarelli, G., Soldovieri, L., Brunetti, M., Avolio, A., Splendore, A., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02539-x · Cited by 52
SGLT2 Inhibitors in Liver Patients
Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48
Pharmacogenetics of novel glucose-lowering drugs
Rathmann, W., & Bongaerts, B. W. C. (2021) · Diabetologia · doi:10.1007/s00125-021-05402-w · Cited by 52
The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
Chew, N., Chong, B., Ng, C. H., Kong, G., Chin, Y. H., Xiao, W., Lee, C. J. M., Dan, Y. Y., Muthiah, M. D., & Foo, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.971484 · Cited by 49
Jin, Z., Yuan, Y., Chen, Z., Liu, S., & Weng, H. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108558 · Cited by 49
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 50
Self-citationVeelen, A., Andriessen, C., den Kamp, Y. J. M. O., Erazo‐Tapia, E., de Ligt, M., Mevenkamp, J., Jörgensen, J. A., Moonen‐Kornips, E., Schaart, G., ESTERLINE, R. L., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155396 · Cited by 48
Self-citationLiver-targeting drugs and their effect on blood glucose and hepatic lipids
Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 48
Jichitu, A., BUNGAU, S. G., Stănescu, A. M. A., Vesa, C. M., Toma, M. M., Bustea, C., Iurciuc, S., Rus, M., Bacalbaşa, N., & Diaconu, C. C. (2021) · Diagnostics · doi:10.3390/diagnostics11040689 · Cited by 47
Metadata
- Authors
- Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., & Oscarsson, J.
- Affiliations
- Uppsala University (SE)
- University of Gothenburg (SE)
- Antaros Medical (Sweden) (SE)
- AstraZeneca (Sweden) (SE)
- Karolinska University Hospital (SE)
- Corresponding author
- Eriksson, Jan W.
- ORCID
- Venue
- Diabetologia
- Published
- 2018-07-03
- Volume
- 61
- Issue
- 9
- Pages
- 1923-1934
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6096619
- OpenAlex
- W2810729752
- Cited by
- 396
- References
- 41
- Citations by year
- 2026: 24 · 2025: 48 · 2024: 48 · 2023: 53 · 2022: 64 · 2021: 54 · 2020: 67 · 2019: 32 · 2018: 5
- FWCI
- 30.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, non-alcoholic fatty liver disease, type 2 diabetes, liver fat, proton density fat fraction, combination therapy, oxidative stress, fibrosis, SLC7A11, SLC17A1
- MeSH terms
- Aged, Benzhydryl Compounds, Carboxylic Acids, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fatty Acids, Female, Glucose, Glucosides, Humans, Inflammation, Liver Function Tests, Magnetic Resonance Imaging, Male, Middle Aged, Sweden, Biomarkers, Oxidative Stress, Hepatocytes, Lipid Metabolism, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
